SDK to Enter Purification Resin Market through Strategic Investment
Showa Denko K.K. (SDK) has signed a strategic partnership agreement with BIA Separations (BIASep), of Austria.
Tokyo, Japan, and Villach, Austria, December 7, 2012 / B3C newswire / - Showa Denko K.K. (SDK) has signed a strategic partnership agreement with BIA Separations (BIASep), of Austria. The partnership includes SDK’s investment in BIASep as well as joint marketing and R&D. With the partnership, SDK will be ready to expand its business to a market of purification resins used for manufacturing biopharmaceuticals and for industrial applications.
SDK is conducting a separation/refining business, developing, manufacturing, and selling various products pertaining to high-performance liquid chromatography (HPLC*). SDK has been providing a wide variety of analytical HPLC columns** with the brand name of “ShodexTM” for more than 40 years. The ShodexTM columns are delivered to wide-ranging customers in the world, including public institutions and R&D/quality control sectors of private enterprises, through the Showa Denko Group’s global sales network.
This time, SDK decided to enter the purification resin market through the strategic partnership with BIASep, expecting to achieve good synergistic effect in terms of both technology and product mix. The market is expected to grow rapidly with the expansion of the biopharmaceutical industry. SDK will fully utilize the technologies it has amassed through the ShodexTM business to enhance the synergies.
Purification resins are used for refining desired components/chemicals from culture/reaction solutions for biopharmaceutical and industrial manufacturing processes. SDK’s protein analysis technology and know-how acquired through the ShodexTM business will be fully utilized, as protein purification plays a key role in the purifying process for biopharmaceuticals.
Efficiency in purification is generally low, resulting in high production costs of biopharmaceuticals. However, BIASep has developed CIM® Monoliths*** (CIM Convective Interaction Media®), which ensure more efficient purification, compared with competitors’ purification resins. SDK has judged that it is best to enter into a tie-up with BIASep to realize a participation in the purification resin market.
Through the partnership arrangement with BIASep, SDK will acquire know-how concerning development, production, quality control, and marketing of purification resins. Furthermore, SDK will aim to strengthen business relations with producers of biopharmaceuticals, thereby expanding its separation/refining business.
*HPLC: A form of chromatography for analyzing compounds. Pressurized liquid is pumped into and passed through a column packed with gels. This process enables efficient separation as well as quick and high-sensitivity detection and determination of various compounds. This technology is applicable to any water- or oil-soluble compounds, and is used in wide areas such as organic chemistry, polymer chemistry, medicine, food, and environmental analysis.
**HPLC columns: Stainless-steel or plastic columns packed with beads gels (spherical particles). A sample to be analyzed (liquid) is injected into the column from one end. Various chemical components contained in the sample are separated, depending on the characteristics of the particles and chemicals, extracted from the column, and analyzed. SDK offers more than 800 different types of HPLC columns.
*** CIM® Monoliths: Block-type formed media for purification and analytics. As various functional groups are attached to the surface, CIM® Monoliths enable more efficient separation and analytics (PAT) of viral particles and large biomolecules (proteins, DNA, etc.) compared to beads gels.
About BIA Separations
Head office: Villach, Austria
Establishment: 1998
Scope of business: Production and sale of short monolithic chromatographic columns based on CIM Convective Interaction Media® Technology
Managing Director and CEO: Dr. Ales Strancar
Number of employees: 80
Related News
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance